PHAR
Pharming Group N.V.
NASDAQ · Healthcare · Biotechnology · NL
$11.23
−2.01%Margins
Gross margin
86.5%
EBITDA margin
11.6%
EBIT margin
3.4%
Net margin
2.5%
FCF margin
8.6%
3.4%
Return on equity
2.0%
Return on assets
3.2%
Return on invested capital
0.77x
Asset turnover
$32.0M
Cash from operations
$2.24
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026